-
1.发明授权公开(公告)号：US09718885B2
公开(公告)日：2017-08-01
申请号：US14796909
申请日：2015-07-10
申请人： Roche GlycArt AG
发明人： Pablo Umaña , Joël Jean-Mairet , James E. Bailey
CPC分类号： C07K16/2887 , C07K16/00 , C07K16/2896 , C07K16/3053 , C07K2317/14 , C07K2317/24 , C07K2317/41 , C07K2317/732 , C07K2319/30 , C12P21/005 , Y10S977/802
摘要： The present invention relates to the field glycosylation engineering of proteins. More particular, the present invention is directed to the glycosylation engineering of proteins to provide proteins with improved therapeutic properties, e.g., antibodies, antibody fragments, or a fusion protein that includes a region equivalent to the Fc region of an immunoglobulin, with enhanced Fc-mediated cellular cytotoxicity.
-
公开(公告)号：US20170174776A1
公开(公告)日：2017-06-22
申请号：US14956268
申请日：2015-12-01
申请人： Roche Glycart AG
发明人： Bernd Bohrmann , Per-Ola Freskgard , Adrian Hugenmatter , Erhard Kopetzki , Ekkehard Moessner , Jens Niewoehner , Hadassah Sumum Sade , Pablo Umaña
IPC分类号： C07K16/28
CPC分类号： C07K16/2881 , A61K2039/54 , C07K2317/77 , C07K2317/92 , C07K2317/94 , C07K2319/00 , C07K2319/30
摘要： Herein is reported a fusion polypeptide comprising i) at least one binding site, e.g. which comprises an antibody heavy chain variable domain and an antibody light chain variable domain, and which binds to an internalizing cell surface receptor, and ii) at least one pharmaceutically active compound, whereby the EC50-value of the binding pair that binds to an internalizing cell surface receptor determined at pH 5.5 is higher than the EC50-value of the same binding pair determined at pH 7.4 and its use for delivering a pharmaceutically active compound across the blood-brain-barrier.
-
3.发明授权公开(公告)号：US09321843B2
公开(公告)日：2016-04-26
申请号：US14665191
申请日：2015-03-23
申请人： Roche GlycArt AG
发明人： Pablo Umaña , Joël Jean-Mairet , James E. Bailey
IPC分类号： C12P21/08 , A61K39/395 , C07K16/30 , C07K16/00 , C07K16/28 , C12N9/10 , C12P21/00 , A61K39/00
CPC分类号： C07K16/2887 , A61K2039/505 , C07K16/00 , C07K16/2896 , C07K16/30 , C07K16/3038 , C07K2317/14 , C07K2317/24 , C07K2317/41 , C07K2317/732 , C12N9/1051 , C12P21/005 , Y02P20/52
摘要： The present invention relates to the field of glycosylation engineering of proteins. More particularly, the present invention relates to glycosylation engineering to generate proteins with improved therapeutic properties, including antibodies with increased antibody-dependent cellular cytotoxicity.
-
4.发明申请公开(公告)号：US20150344584A1
公开(公告)日：2015-12-03
申请号：US14577180
申请日：2014-12-19
申请人： Roche GlycArt AG
发明人： Pablo Umaña , Ekkehard Mössner
IPC分类号： C07K16/28
CPC分类号： C07K16/2887 , A61K2039/505 , C07K2317/21 , C07K2317/24 , C07K2317/41 , C07K2317/52 , C07K2317/522 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/732 , C07K2317/734 , C12N2510/02
摘要： The present invention relates to modified antigen binding molecules (ABMs). In particular embodiments, the present invention relates to recombinant monoclonal antibodies or fragments, including chimeric, primatized or humanized antibodies or fragments, having altered ability to mediate cell signaling activity by a target antigen, and/or altered ability to mediate cross-linking of one or more target antigens. In addition, the present invention relates to nucleic acid molecules encoding such modified ABMs, and vectors and host cells comprising such nucleic acid molecules. The invention further relates to methods for producing the modified ABMs of the invention, and to methods of using these modified ABMs in treatment of disease. In addition, the present invention relates to modified ABMs with modified glycosylation having improved therapeutic properties, including antibodies with increased Fc receptor binding and increased effector function.
摘要翻译： 本发明涉及修饰的抗原结合分子（ABM）。 在具体实施方案中，本发明涉及重组单克隆抗体或片段，包括嵌合，灵长类或人源化抗体或片段，具有改变的能力以介导目标抗原的细胞信号传导活性，和/或改变的介导一种 或更多的靶抗原。 此外，本发明涉及编码这种修饰的ABM的核酸分子以及包含这种核酸分子的载体和宿主细胞。 本发明还涉及生产本发明的修饰的ABM的方法，以及使用这些修饰的ABM在治疗疾病中的方法。 此外，本发明涉及具有改进的治疗性质的具有改性糖基化的修饰的ABM，包括具有增加的Fc受体结合和增加的效应子功能的抗体。
-
5.发明授权Fusion constructs and use of same to produce antibodies with increased Fc receptor binding affinity and effector function 有权融合构建体及其使用以产生具有增加的Fc受体结合亲和力和效应子功能的抗体公开(公告)号：US08859234B2
公开(公告)日：2014-10-14
申请号：US13759925
申请日：2013-02-05
申请人： Roche GlycArt AG
发明人： Pablo Umaña , Peter Bruenker , Claudia Ferrara , Tobias Suter
IPC分类号： C12P21/04 , C12P21/08 , C07K16/28 , C12N9/24 , C07K16/30 , C12N15/62 , C12N9/10 , C07K16/32 , C12P21/00 , A61K38/00 , A61K39/00
CPC分类号： C07K16/2887 , A61K38/00 , A61K2039/505 , C07K16/28 , C07K16/2863 , C07K16/2896 , C07K16/30 , C07K16/32 , C07K2317/24 , C07K2317/41 , C07K2317/732 , C07K2319/05 , C12N9/1051 , C12N9/2488 , C12N15/62 , C12P21/005 , C12Y204/01038 , C12Y204/01144 , C12Y302/01024 , C12Y302/01096 , C12Y302/01114
摘要： The present invention relates to the field of glycosylation engineering of proteins. More particularly, the present invention relates to nucleic acid molecules, including fusion constructs, having catalytic activity and the use of same in glycosylation engineering of host cells to generate polypeptides with improved therapeutic properties, including antibodies with increased Fc receptor binding and increased effector function.
摘要翻译： 本发明涉及蛋白质的糖基化工程领域。 更具体地说，本发明涉及具有催化活性的核酸分子，包括具有催化活性的核糖分子，以及其在宿主细胞的糖基化工程中的用途，以产生具有改善的治疗性质的多肽，包括具有增加的Fc受体结合和增加的效应子功能的抗体。
-
6.发明申请公开(公告)号：US20160272719A1
公开(公告)日：2016-09-22
申请号：US15080020
申请日：2016-03-24
申请人： Roche GlycArt AG
发明人： Pablo Umaña , Joël Jean-Mairet , James E. Bailey
CPC分类号： C07K16/2887 , A61K2039/505 , C07K16/00 , C07K16/2896 , C07K16/30 , C07K16/3038 , C07K2317/14 , C07K2317/24 , C07K2317/41 , C07K2317/732 , C12N9/1051 , C12P21/005 , Y02P20/52
摘要： The present invention relates to the field of glycosylation engineering of proteins. More particularly, the present invention relates to glycosylation engineering to generate proteins with improved therapeutic properties, including antibodies with increased antibody-dependent cellular cytotoxicity.
-
7.发明申请公开(公告)号：US20160130347A1
公开(公告)日：2016-05-12
申请号：US14434168
申请日：2013-10-03
申请人： ROCHE GLYCART AG
发明人： Peter Bruenker , Tanja Fauti , Christiane Jaeger , Christian Klein , Pablo Umaña
CPC分类号： C07K16/2809 , A61K39/39541 , A61K39/39558 , A61K2039/505 , C07K16/18 , C07K16/30 , C07K16/3053 , C07K16/468 , C07K2317/31 , C07K2317/33 , C07K2317/52 , C07K2317/54 , C07K2317/55 , C07K2317/66 , C07K2317/75 , C07K2317/92 , C07K2317/94 , C07K2319/00
摘要： The present invention relates to bispecific antibodies comprising at least two Fab fragments, wherein the first Fab fragment comprises at least one antigen binding site specific for a first antigen; and the second Fab fragment comprises at least one antigen binding site specific for a second antigen, wherein either the variable regions or the constant regions of the second Fab heavy and light chain are exchanged and the two Fab fragments are connected to each other by two peptide linkers; and wherein the bispecific antibody is devoid of a Fc domain; methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
摘要翻译： 本发明涉及包含至少两个Fab片段的双特异性抗体，其中第一Fab片段包含至少一个对第一抗原具有特异性的抗原结合位点; 并且第二Fab片段包含至少一个针对第二抗原特异性的抗原结合位点，其中第二Fab重链和轻链的可变区或恒定区被交换，并且两个Fab片段通过两个肽相互连接 接头; 并且其中所述双特异性抗体缺乏Fc结构域; 其制备方法，含有所述抗体的药物组合物及其用途。
-
公开(公告)号：US20190106497A1
公开(公告)日：2019-04-11
申请号：US15965143
申请日：2018-04-27
申请人： Roche GlycArt AG
发明人： Pablo Umaña , Ekkehard MÖSSNER
摘要： The present invention relates to antigen binding molecules (ABMs). In particular embodiments, the present invention relates to recombinant monoclonal antibodies, including chimeric, primatized or humanized antibodies specific for human EGFR. In addition, the present invention relates to nucleic acid molecules encoding such ABMs, and vectors and host cells comprising such nucleic acid molecules. The invention further relates to methods for producing the ABMs of the invention, and to methods of using these ABMs in treatment of disease. In addition, the present invention relates to ABMs with modified glycosylation having improved therapeutic properties, including antibodies with increased Fc receptor binding and increased effector function.
-
公开(公告)号：US10087250B2
公开(公告)日：2018-10-02
申请号：US14434168
申请日：2013-10-03
申请人： Roche Glycart AG
摘要： The present invention relates to bispecific antibodies comprising at least two Fab fragments, wherein the first Fab fragment comprises at least one antigen binding site specific for a first antigen; and the second Fab fragment comprises at least one antigen binding site specific for a second antigen, wherein either the variable regions or the constant regions of the second Fab heavy and light chain are exchanged and the two Fab fragments are connected to each other by two peptide linkers; and wherein the bispecific antibody is devoid of a Fc domain; methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
-
公开(公告)号：US09957326B2
公开(公告)日：2018-05-01
申请号：US15050821
申请日：2016-02-23
申请人： Roche GlycArt AG
发明人： Pablo Umaña , Ekkehard Mössner
CPC分类号： C07K16/2863 , A61K38/179 , A61K45/06 , A61K47/6803 , A61K47/6817 , A61K2039/505 , C07K2317/21 , C07K2317/41 , C07K2317/52 , C07K2317/565 , C07K2317/732 , C07K2319/00
摘要： The present invention relates to antigen binding molecules (ABMs). In particular embodiments, the present invention relates to recombinant monoclonal antibodies, including chimeric, primatized or humanized antibodies specific for human EGFR. In addition, the present invention relates to nucleic acid molecules encoding such ABMs, and vectors and host cells comprising such nucleic acid molecules. The invention further relates to methods for producing the ABMs of the invention, and to methods of using these ABMs in treatment of disease. In addition, the present invention relates to ABMs with modified glycosylation having improved therapeutic properties, including antibodies with increased Fc receptor binding and increased effector function.
-
-
-
-
-
-
-
-
-
搜索结果
13 条记录 (耗时 0.029 秒)
